Stockreport

OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain [Yahoo! Finance]

OKYO Pharma Limited - Ordinary Shares  (OKYO) 
PDF OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain [Read more]